Patents by Inventor Susan Lorey

Susan Lorey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PRONGF MUTANTS AND USES THEREOF IN THE PRODUCTION OF BETA-NGF
    Publication number: 20200031893
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 30, 2020
    Inventors: Susan LOREY, Bernhard JANOWSKI, Heiko PULTKE, Daniela KATHMANN, Antje PARTHIER, Andreas ANTON
  • ProNGF mutants and uses thereof in the production of beta-NGF
    Patent number: 10308694
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 4, 2019
    Assignee: Wacker Chemie AG
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • ProNGF mutants and uses thereof in the production of beta-NGF
    Patent number: 9617322
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: April 11, 2017
    Assignee: Wacker Chemie AG
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • NOVEL PRONGF MUTANTS AND USES THEREOF IN THE PRODUCTION OF BETA-NGF
    Publication number: 20160244496
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 25, 2016
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton
  • HUMAN FUSION PROTEINS COMPRISING SINGLE CHAIN TNFALPHA AND TARGETING DOMAINS
    Publication number: 20150183846
    Abstract: The present invention relates to fusion proteins in which a biologically active moiety is linked to a targeting domain. The invention specifically concerns fusion proteins comprising single-chain (sc) TNFalpha monomers as biologically active moiety and a specific targeting domain, preferably fusion proteins comprising at least three scTNFalpha monomers and modified hetero-dimeric ubiquitin proteins with high affinity to target molecules (Affilin® molecules). The invention further relates to these fusion proteins for use in medicine, in particular in the treatment of cancer. The invention is further directed to pharmaceutical compositions comprising such fusion proteins in combination with chemotherapeutics agents.
    Type: Application
    Filed: June 13, 2013
    Publication date: July 2, 2015
    Applicant: Scil Proteins GmbH
    Inventors: Christian Lange, Manja Gloser, Susan Lorey, Markus Fiedler
  • NOVEL PRONGF MUTANTS AND USES THEREOF IN THE PRODUCTION OF BETA-NGF
    Publication number: 20150087020
    Abstract: The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R1SK3R4 at least at positions R1 and K3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.
    Type: Application
    Filed: December 19, 2012
    Publication date: March 26, 2015
    Applicant: WACKER CHEMIE AG
    Inventors: Susan Lorey, Bernhard Janowski, Heiko Pultke, Daniela Kathmann, Antje Parthier, Andreas Anton